# Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

> **NCT05029609** · PHASE1 · WITHDRAWN · sponsor: **Tiziana Life Sciences LTD**

## Conditions studied

- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Multiple Sclerosis

## Interventions

- **DRUG:** Intranasal Foralumab Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05029609
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2022-11
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to business reasons
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029609, "Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05029609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*